Prospective Observational Cohort Study for Predicting Unruptured Intracranial Aneurysm Rupture Risk Using Blood Pressure Variability and 3D Structural Evolution

NCT07893574 · tracked via the Priya Life Science China tracker

Sponsor

Beijing Tiantan Hospital

Phase

Observational

Started

2025-01-01

Last updated

2026-10-26

Condition(s) studied

Unruptured Intracranial AneurysmIntracranial Aneurysm Rupture

Study summary

This is a single-center, prospective, longitudinal observational cohort study in adults with unruptured intracranial aneurysms (UIAs) who are managed by conservative observation rather than immediate surgery or endovascular treatment. The study aims to build a time-series dataset combining blood pressure variability (BPV) and three-dimensional (3D) aneurysm morphological evolution, and to develop deep-learning models using long short-term memory (LSTM) and Transformer networks to predict aneurysm rupture risk. A secondary aim is to compare the new models with traditional scores such as PHASES and to explore how BPV relates to 3D aneurysm change.Participants aged 18-80 years with UIA confirmed by CTA, MRA, or DSA and judged suitable for conservative follow-up will be enrolled consecutively at the study site. Those with imaging contraindications, other major cerebrovascular diseases such as moyamoya or arteriovenous malformation, or severe organ dysfunction are excluded. No study-driven intervention is imposed; routine clinical care continues. Baseline data include demographics, hypertension history, laboratory tests, 24-hour ambulatory blood pressure, home blood pressure for 7 days, optional wearable monitoring, and CTA/MRA/DSA for 3D aneurysm parameters such as volume, surface area, compactness, and sphericity. BPV is summarized using standard deviation, coefficient of variation, and variability independent of the mean.Participants scheduled for in-hospital visits provide written informed consent and are followed at 6, 12, 24, 36, 48, 72, 96, and 120 months with repeated BPV measurement and imaging. Participants who already have at least two qualifying imaging and blood-pressure records before enrollment and will not return for in-person visits provide verbal consent and are followed by telephone every 6-12 months to confirm health status and rupture/growth events. All data are entered into a REDCap system with automated and manual quality checks. A historical institutional dataset (CAIASA) may be used only for algorithm pretraining and is not counted as the prospective enrollment target.The primary outcome is UIA rupture confirmed by CT or surgery. Secondary outcomes include aneurysm growth defined as diameter increase ≥1 mm, changes in 3D morphological parameters over time, BPV trends, and incremental predictive performance versus PHASES using AUC, IDI, and NRI with bootstrapping validation. A data safety monitoring committee oversees safety and data integrity. Findings are expected to support individualized follow-up and treatment decisions for people with unruptured aneurysms.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Age 18 to 80 years at enrollment. * Diagnosis of one or more unruptured intracranial aneurysms confirmed by CT angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA). * Managed by conservative observation (no prophylactic clipping, coiling, stent-assisted coiling, or flow diversion) as decided by the treating neurovascular team. * Able and willing to undergo repeated blood pressure variability assessment and imaging follow-up, including 24-hour ambulatory blood pressure and CTA/MRA/DSA as clinically indicated. * Provides written informed consent if planning in-hospital follow-up, or oral informed consent if only telephone follow-up and prior complete data are available per protocol. * For participants without preexisting repeat imaging and blood pressure data, willing to attend hospital follow-up at 6, 12, 24, 36, 48, 72, 96, and 120 months; all participants agree to telephone follow-up every 6 to 12 months. Exclusion Criteria: * Known allergy to iodinated contrast or other contraindications preventing CTA/DSA, or contraindications to MRA/contrast preventing required imaging. * Severe renal impairment, contraindicated for required contrast-enhanced imaging per investigator judgment. * Other clinically significant cerebrovascular diseases that confound aneurysm natural history, including moyamoya disease, arteriovenous malformation, arteriovenous fistula, or symptomatic intracranial stenosis. * Dissecting, traumatic, mycotic, or tumor-associated aneurysms, or aneurysms secondary to infective/inflammatory arteriopathy. * Severe hepatic, cardiac, renal, respiratory, hematologic, or other systemic organ dysfunction that would preclude follow-up or bias blood pressure/imaging data. * Expected survival less than 6 months due to non-cerebral disease. * Inability to provide informed consent, inability to communicate, severe psychiatric disease, or no available telephone/contact for follow-up. * Already enrolled in another UIA interventional trial that prohibits concurrent observation registration, or prior prophylactic treatment of all enrolled aneurysms.

Primary outcome measure(s)

Incidence of unruptured intracranial aneurysm rupture confirmed by CT or intraoperative findings — From enrollment through 6, 12, 24, 36, 48, 72, 96 and 120 months of follow-up, up to 10 years
Rupture is defined as subarachnoid hemorrhage or aneurysm bleeding confirmed by non-contrast CT, CT angiography, DSA, or intraoperative findings in participants under conservative observation. Reported as number/percentage of aneurysms or participants with rupture and annualized rupture rate; time-to-event analyzed from enrollment.

Trial sites (1)

Facility	City	Region	Status
Beijing Tiantan Hospital, Capital Medical University	Beijing	China	Recruiting

More Beijing Tiantan Hospital trials in China

Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma Active, not recruiting

Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) Recruiting

Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY) Recruiting

Risk Prediction Model for Cerebrovascular Events in Carotid Artery Stenosis Enrolling by invitation

The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia Recruiting

Other trials for the same condition

INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) Recruiting

Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Postoperative Headache Following Stent-Assisted Coiling of Unruptured Intracranial Aneurysms Recruiting

Early Complications After Flow Diverter Versus Stent-Assisted Coiling for Unruptured Wide-Neck Intracranial Bifurcation Aneurysms Recruiting

Investigation of Protein Heterogeneity in Extracellular Vesicles Derived From Different Human Blood Circulatory Regions Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07893574 on ClinicalTrials.gov ↗ ← All trials in China